Phase 3 Study Journal

63
ASO score
Text
63/100
Graphic
45/100
Reviews
78/100
Other
73/100
Support our team
Additional Information
Rating:
3.05
Voted: 187
Website:
Email:
Privacy Policy:
Categories: Medical
Size: 117MB
Installs: 20.16K
App Age: 1 year 6 months
Release Date: Feb 18, 2021
Last Update: Aug 16, 2021
Version: 1.1.3
Version history
1.1.3
Aug 16, 2021
Performance Enhancement.
1.1.2
May 10, 2021
Bugfixes
Version history
1.1.3
Aug 16, 2021
Performance Enhancement.
1.1.2
May 10, 2021
Bugfixes
1.0
Mar 23, 2021
- Bug fixes
0
Feb 18, 2021
First release

All Rankings

All
New
Trending Up
Trending Down
All
Jul 31, 2022
Aug 07, 2022
Load more
New
Jul 31, 2022
Aug 07, 2022
Load more
Trending Up
Jul 31, 2022
Aug 07, 2022
Load more
Trending Down
Jul 31, 2022
Aug 07, 2022
Load more

Downloads

Downloads Graph
Downloads icon
Total
20.2K
Last month icon
Last month
5.3K

Text ASO

English
Afrikaans
Amharic
Arabic
Azeri
Belarusian
Bulgarian
Bangla
Catalan
Czech
Danish
German
Greek
English
English (Australia)
English (Canada)
English (United Kingdom)
English (India)
English (Singapore)
English (South Africa)
Spanish
Spanish (Latin America)
Spanish (Mexico)
Spanish (United States)
Estonian
Basque (Spain)
Persian
Persian (United Arab Emirates)
Persian (Afghanistan)
Persian (Iran)
Finnish
Filipino
French
French (Canada)
Galician (Spain)
Gujarati
Hebrew
Hindi
Croatian
Hungarian
Armenian
Indonesian
Icelandic
Italian
Japanese
Georgian (Georgia)
Kazakh
Khmer (Cambodia)
Kannada (India)
Korean
Kyrgyz
Lao
Lithuanian
Latvian
Macedonian
Malayalam (India)
Mongolian
Marathi (India)
Malay
Burmese (Myanmar [Burma]) (Myanmar)
Norwegian Bokmål
Nepali (Nepal)
Dutch
Norwegian
Punjabi
Polish
Portuguese
Portuguese (Brazil)
Romanian
Russian
Sinhala (Sri Lanka)
Slovak
Slovenian
Albanian
Serbian
Swedish
Swahili
Tamil (India)
Telugu (India)
Thai
Turkish
Ukrainian
Urdu
Vietnamese
Chinese
Chinese (Hong Kong)
Chinese (Taiwan)
Zulu
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 0 of 50
)
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Title (
Characters: 21 of 50
)
Phase 3 Study Journal
Short Description (
Characters: 73 of 80
)
Hierdie app is bedoel om saam met die Medicago 021 Fase 3-studie te werk.
Short Description (
Characters: 53 of 80
)
ይህ መተግበሪያ ከሜዲጎጎ 021 ደረጃ 3 ጥናት ጋር አብሮ ለመስራት የታሰበ ነው ፡፡
Short Description (
Characters: 71 of 80
)
يهدف هذا التطبيق إلى العمل جنبًا إلى جنب مع دراسة Medicago 021 Phase 3.
Short Description (
Characters: 66 of 80
)
Bu tətbiq Medicago 021 Phase 3 Study ilə birlikdə işləmək üçündür.
Short Description (
Characters: 79 of 80
)
Гэта дадатак прызначана для працы сумесна з даследаваннем Medicago 021 Phase 3.
Short Description (
Characters: 86 of 80
)
Това приложение е предназначено да работи заедно с проучването Фаза 3 на Medicago 021.
Short Description (
Characters: 72 of 80
)
এই অ্যাপ্লিকেশনটি মেডিকাগো 021 ফেজ 3 স্টাডির সাথে কাজ করে বোঝানো হয়েছে।
Short Description (
Characters: 101 of 80
)
Aquesta aplicació està pensada per funcionar conjuntament amb l'estudi de fase 3 de Medicago 021.
Short Description (
Characters: 67 of 80
)
Tato aplikace má fungovat ve spojení se studií fáze 3 Medicago 021.
Short Description (
Characters: 82 of 80
)
Denne app er beregnet til at arbejde sammen med Medicago 021 fase 3-undersøgelsen.
Short Description (
Characters: 79 of 80
)
Diese App soll in Verbindung mit der Medicago 021 Phase 3-Studie funktionieren.
Short Description (
Characters: 77 of 80
)
Αυτή η εφαρμογή προορίζεται να συνεργαστεί με τη Μελέτη Φάσης 3 Medicago 021.
Short Description (
Characters: 77 of 80
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Short Description (
Characters: 77 of 80
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Short Description (
Characters: 77 of 80
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Short Description (
Characters: 77 of 80
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Short Description (
Characters: 77 of 80
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Short Description (
Characters: 77 of 80
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Short Description (
Characters: 77 of 80
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Short Description (
Characters: 90 of 80
)
Esta aplicación está destinada a funcionar junto con el estudio de fase 3 de Medicago 021.
Short Description (
Characters: 90 of 80
)
Esta aplicación está destinada a funcionar junto con el estudio de fase 3 de Medicago 021.
Short Description (
Characters: 90 of 80
)
Esta aplicación está destinada a funcionar junto con el estudio de fase 3 de Medicago 021.
Short Description (
Characters: 90 of 80
)
Esta aplicación está destinada a funcionar junto con el estudio de fase 3 de Medicago 021.
Short Description (
Characters: 69 of 80
)
See rakendus on mõeldud töötama koos Medicago 021 3. faasi uuringuga.
Short Description (
Characters: 80 of 80
)
Aplikazio honek Medicago 021 3. fasea azterketarekin batera funtzionatu nahi du.
Short Description (
Characters: 63 of 80
)
این برنامه قرار است همراه با مطالعه فاز 3 Medicago 021 کار کند.
Short Description (
Characters: 63 of 80
)
این برنامه قرار است همراه با مطالعه فاز 3 Medicago 021 کار کند.
Short Description (
Characters: 63 of 80
)
این برنامه قرار است همراه با مطالعه فاز 3 Medicago 021 کار کند.
Short Description (
Characters: 63 of 80
)
این برنامه قرار است همراه با مطالعه فاز 3 Medicago 021 کار کند.
Short Description (
Characters: 87 of 80
)
Tämän sovelluksen on tarkoitus toimia yhdessä Medicago 021 Phase 3 -tutkimuksen kanssa.
Short Description (
Characters: 77 of 80
)
Ang app na ito ay sinadya upang gumana kasabay ng Medicago 021 Phase 3 Study.
Short Description (
Characters: 102 of 80
)
Cette application est conçue pour fonctionner en conjonction avec l'étude de phase 3 Medicago 021.
Short Description (
Characters: 102 of 80
)
Cette application est conçue pour fonctionner en conjonction avec l'étude de phase 3 Medicago 021.
Short Description (
Characters: 85 of 80
)
Esta aplicación está destinada a funcionar xunto co estudo de fase 3 de Medicago 021.
Short Description (
Characters: 71 of 80
)
આ એપ્લિકેશન મેડિકોગો 021 ફેઝ 3 અધ્યયન સાથે જોડાણમાં કાર્ય કરવા માટે છે.
Short Description (
Characters: 57 of 80
)
יישום זה נועד לעבוד בשיתוף עם מחקר שלב 3 של Medicago 021.
Short Description (
Characters: 63 of 80
)
यह ऐप मेडिकैगो 021 फेज 3 स्टडी के साथ मिलकर काम करने के लिए है।
Short Description (
Characters: 76 of 80
)
Ova je aplikacija namijenjena radu zajedno sa studijom Medicago 021 Phase 3.
Short Description (
Characters: 70 of 80
)
Ez az alkalmazás a Medicago 021 3. fázisú vizsgálattal együtt működik.
Short Description (
Characters: 83 of 80
)
Այս ծրագիրը նախատեսված է աշխատել Medicago 021 փուլ 3 ուսումնասիրության հետ համատեղ:
Short Description (
Characters: 91 of 80
)
Aplikasi ini dimaksudkan untuk bekerja dalam hubungannya dengan Studi Medicago 021 Tahap 3.
Short Description (
Characters: 78 of 80
)
Þessu forriti er ætlað að vinna í tengslum við Medicago 021 3. stigs rannsókn.
Short Description (
Characters: 89 of 80
)
Questa app è pensata per funzionare in combinazione con lo studio di fase 3 Medicago 021.
Short Description (
Characters: 46 of 80
)
このアプリは、Medicago021フェーズ3研究と連携して動作することを目的としています。
Short Description (
Characters: 67 of 80
)
ეს აპი მიზნად ისახავს იმუშაოს Medicago 021 ფაზა 3 კვლევასთან ერთად.
Short Description (
Characters: 72 of 80
)
Бұл қосымша Medicago 021 Phase 3 Study-мен бірге жұмыс істеуге арналған.
Short Description (
Characters: 86 of 80
)
កម្មវិធីនេះត្រូវបានបង្កើតឡើងដើម្បីភ្ជាប់ជាមួយការសិក្សាឌឹហ្គោហ្គោ 021 ​​ដំណាក់កាលទី 3 ។
Short Description (
Characters: 72 of 80
)
ಈ ಅಪ್ಲಿಕೇಶನ್ ಮೆಡಿಕಾಗೊ 021 ಹಂತ 3 ಅಧ್ಯಯನದೊಂದಿಗೆ ಕೆಲಸ ಮಾಡಲು ಉದ್ದೇಶಿಸಲಾಗಿದೆ.
Short Description (
Characters: 43 of 80
)
이 앱은 Medicago 021 3 상 연구와 함께 작동하도록 설계되었습니다.
Short Description (
Characters: 74 of 80
)
Бул колдонмо Medicago 021 Phase 3 Study менен биргеликте иштөөгө арналган.
Short Description (
Characters: 64 of 80
)
ແອັບນີ້ມີຄວາມ ໝາຍ ວ່າເຮັດວຽກຮ່ວມກັບການສຶກສາ Medicago 021 ໄລຍະ 3.
Short Description (
Characters: 65 of 80
)
Ši programa skirta veikti kartu su „Medicago 021“ 3 fazės tyrimu.
Short Description (
Characters: 71 of 80
)
Šī lietotne ir paredzēta darbam kopā ar Medicago 021 3. fāzes pētījumu.
Short Description (
Characters: 80 of 80
)
Оваа апликација е наменета да работи заедно со студијата Фаза 3 на Медигаго 021.
Short Description (
Characters: 87 of 80
)
ഈ അപ്ലിക്കേഷൻ മെഡിഗാഗോ 021 ഘട്ടം 3 പഠനവുമായി ചേർന്ന് പ്രവർത്തിക്കാൻ ഉദ്ദേശിച്ചുള്ളതാണ്.
Short Description (
Characters: 88 of 80
)
Энэхүү аппликейшн нь Medicago 021 Phase 3 Study програмтай хамтран ажиллах зориулалттай.
Short Description (
Characters: 69 of 80
)
हे अ‍ॅप मेडिकोगो 021 फेज 3 अभ्यासाच्या संयोगाने कार्य करण्यासाठी आहे.
Short Description (
Characters: 79 of 80
)
Aplikasi ini bertujuan untuk bekerja bersama dengan Kajian Fasa 3 Medicago 021.
Short Description (
Characters: 82 of 80
)
ဤအက်ပလီကေးရှင်းကို Medicago 021 အဆင့် 3 လေ့လာမှုနှင့်တွဲဖက်လုပ်ဆောင်ရန်ရည်ရွယ်သည်။
Short Description (
Characters: 69 of 80
)
Denne appen er ment å fungere sammen med Medicago 021 fase 3-studien.
Short Description (
Characters: 77 of 80
)
यो अनुप्रयोग मेडिकेगो ०२१ चरण Study अध्ययनको साथ संयोजनको रूपमा काम गर्ने हो।
Short Description (
Characters: 73 of 80
)
Deze app is bedoeld om samen te werken met de Medicago 021 Phase 3 Study.
Short Description (
Characters: 69 of 80
)
Denne appen er ment å fungere sammen med Medicago 021 fase 3-studien.
Short Description (
Characters: 53 of 80
)
ਇਹ ਐਪ ਮੈਡੀਕਾਗੋ 021 ਫੇਜ਼ 3 ਸਟੱਡੀ ਦੇ ਨਾਲ ਕੰਮ ਕਰਨ ਲਈ ਹੈ.
Short Description (
Characters: 82 of 80
)
Ta aplikacja jest przeznaczona do pracy w połączeniu z Medicago 021 Phase 3 Study.
Short Description (
Characters: 82 of 80
)
Este aplicativo deve funcionar em conjunto com o Estudo de Fase 3 do Medicago 021.
Short Description (
Characters: 82 of 80
)
Este aplicativo deve funcionar em conjunto com o Estudo de Fase 3 do Medicago 021.
Short Description (
Characters: 88 of 80
)
Această aplicație este menită să funcționeze împreună cu studiul de fază 3 Medicago 021.
Short Description (
Characters: 88 of 80
)
Это приложение предназначено для работы в сочетании с исследованием фазы 3 Medicago 021.
Short Description (
Characters: 71 of 80
)
මෙම යෙදුම මෙඩිකාගෝ 021 අදියර 3 අධ්‍යයනයට සමගාමීව වැඩ කිරීමට අදහස් කෙරේ.
Short Description (
Characters: 82 of 80
)
Táto aplikácia je určená na prácu v spojení so štúdiou Medicago 021 Phase 3 Study.
Short Description (
Characters: 71 of 80
)
Ta aplikacija naj bi delovala v povezavi s študijo faze 3 Medicago 021.
Short Description (
Characters: 86 of 80
)
Ky aplikacion ka për qëllim të punojë së bashku me Studimin e Fazës 3 të Medicago 021.
Short Description (
Characters: 74 of 80
)
Ова апликација је намењена раду у сарадњи са студијом Фаза 3 Медицаго 021.
Short Description (
Characters: 78 of 80
)
Den här appen är tänkt att fungera tillsammans med Medicago 021 fas 3-studien.
Short Description (
Characters: 96 of 80
)
Programu hii imekusudiwa kufanya kazi kwa kushirikiana na Utafiti wa Awamu ya 3 ya Medicago 021.
Short Description (
Characters: 69 of 80
)
இந்த பயன்பாடு மெடிகாகோ 021 கட்டம் 3 ஆய்வோடு இணைந்து செயல்பட வேண்டும்.
Short Description (
Characters: 75 of 80
)
ఈ అనువర్తనం మెడికాగో 021 దశ 3 అధ్యయనంతో కలిసి పనిచేయడానికి ఉద్దేశించబడింది.
Short Description (
Characters: 57 of 80
)
แอพนี้มีไว้เพื่อทำงานร่วมกับการศึกษา Medicago 021 Phase 3
Short Description (
Characters: 87 of 80
)
Bu uygulama, Medicago 021 Aşama 3 Çalışması ile birlikte çalışmak üzere tasarlanmıştır.
Short Description (
Characters: 78 of 80
)
Ця програма призначена для роботи спільно з дослідженням Medicago 021 Phase 3.
Short Description (
Characters: 66 of 80
)
اس ایپ کا مطلب میڈیکیگو 021 فیز 3 اسٹڈی کے ساتھ مل کر کام کرنا ہے۔
Short Description (
Characters: 84 of 80
)
Ứng dụng này có nghĩa là hoạt động cùng với Nghiên cứu Giai đoạn 3 của Medicago 021.
Short Description (
Characters: 30 of 80
)
该应用程序旨在与Medicago 021阶段3研究结合使用。
Short Description (
Characters: 0 of 80
)
Short Description (
Characters: 30 of 80
)
該應用程序旨在與Medicago 021階段3研究結合使用。
Short Description (
Characters: 90 of 80
)
Lolu hlelo lokusebenza luhloselwe ukusebenza ngokubambisana ne-Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 0 of 4000
)
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.
Description (
Characters: 77 of 4000
)
This app is meant to work in conjunction with the Medicago 021 Phase 3 Study.

Visual ASO

Screenshots

Phase 3 Study Journal for Android Screenshot #1
Phase 3 Study Journal for Android Screenshot #2
Phase 3 Study Journal for Android Screenshot #3
Phase 3 Study Journal for Android Screenshot #4
Phase 3 Study Journal for Android Screenshot #5
Phase 3 Study Journal for Android Screenshot #6
Phase 3 Study Journal for Android Screenshot #7
Phase 3 Study Journal for Android Screenshot #8

Compare with Category Top Apps

Metrics
Current App
Category Top Average
Difference
Screenshots
Current App: 8
Category Top Average: 15
-7
Videos
Current App: no video
Category Top Average: 34% has videos
-

Rating & Reviews

Reviews Overview
🧐 Coming Soon…
Rating
3
187 voters

Reviews

Compare with Category Top Apps

Metrics
Current App
Category Top Average
Difference
Rating
Current App: 3.00
Category Top Average: 4.00
-1.00
Voted
Current App: 187
Category Top Average: 0
+187

More by snapIoT Inc

RGN Amb 40 PaTHway Subject App 36 Medicago 021 Subject App 60

Compare with Category Top Apps

Metrics
Current App
Category Top Average
Difference
Size (MB)
Current App: 117MB
Category Top Average: 84MB
+32MB
Update frequency (d)
Current App: 59
Category Top Average: 211
-152

Availability in countries

      AFRICA
      5
      🇬🇧United Kingdom
      EUROPE
      1
      🇬🇧United Kingdom
      🇬🇧United Kingdom
      🇬🇧United Kingdom
      🇬🇧United Kingdom
      🇬🇧United Kingdom
      🇬🇧United Kingdom

      How to download Phase 3 Study Journal for Android?

      This app is available for Android, so you can log into your Google Play, find it and start downloading.

      Easy way to install Phase 3 Study Journal on smartphone from Asolytics. Just click on ”Get the app” button.

      Phase 3 Study Journal statistics

      Phase 3 Study Journal rating on Google Play is 3.05. According to Phase 3 Study Journal reviews app has 187 votes. On Asolytics you can read reviews of users and sort on:

      • negative
      • positive
      • negative without answers

      Latest update was on Aug 16, 2021.

      Who created Phase 3 Study Journal?

      The developer name is snapIoT Inc. Age of application is 1 year 6 months.

      Check all data and compare with others by Asolytics.

      Ranking
      Text ASO
      Graphic ASO
      Reviews ASO
      Other ASO
      Email
      Password
      Name
      Last Name
      Email
      Password
      Repeat password
      Choose your position
      Reset Password
      We’ll email you instructions on how to reset your password.
      Email
      Back to Log in
      Reset Password
      Instruction have been sent to demkitu@jig.org.
      Please check your email.